
Illumina (ILMN) Stock Forecast & Price Target
Illumina (ILMN) Analyst Ratings
Bulls say
Illumina has historically demonstrated a strong ability to increase revenue by leveraging demand elasticity, where the incremental demand for sequencing outweighs pricing declines, suggesting robust market dynamics. The company aims for high single-digit revenue growth by 2027, supported by its innovative multiomic technologies and a solid product roadmap, which indicates a proactive approach to enhancing market presence. Additionally, despite challenges in the Chinese market, Illumina is projected to achieve approximately 14% EPS growth in 2026, illustrating underlying financial strength and resilience in its operational performance.
Bears say
Illumina has lowered its 2025 guidance for non-GAAP diluted EPS to $4.50, reflecting reduced earnings contributions from China and current macroeconomic challenges, signaling potential ongoing revenue headwinds. The company's stock has declined approximately 40% since solid Q4'24 results due to fears over possible operational constraints in China, which represents about 7% of its sales, and concerns about competitive pressures and NIH funding cuts. Furthermore, if Illumina cannot achieve revenue or earnings growth comparable to its life science tools peers, it may face continued trading at a relative discount, further complicating its financial outlook.
This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.
Illumina (ILMN) Analyst Forecast & Price Prediction
Start investing in Illumina (ILMN)
Order type
Buy in
Order amount
Est. shares
0 shares